Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 54, Issue 74, 2007, Pages 518-521

  Kuroda, Makoto ^a   Kobayashi, Yoshinao ^a,b   Urawa, Naohito ^a   Yamamoto, Mika ^a   Mifuji, Rumi ^a   Araki, Jun ^a   Tanaka, Hideaki ^a   Horiike, Shinichiro ^a   Itani, Toshio ^a   Fujita, Naoki ^a   Konishi, Masayoshi ^a   Iwasa, Motoh ^a   Kaito, Masahiko ^a   Adachi, Yukihiko ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

5 fluorouracil; Hepatitis C virus; Hepatocellular carcinoma; Interferon alpha

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; TUMOR MARKER;

ANOREXIA; ARTICLE; ASCITES; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG FATALITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FAILURE; MALE; PRIORITY JOURNAL; SCORING SYSTEM; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRA-ARTERIAL; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; PORTAL VEIN; SURVIVAL RATE;

EID: 34248136840     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kogure T, Ueno Y, Iwasaki T, Shimosegawa T: The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol 2004; 53:296-304.
2. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alpha-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21:421-427.
3. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer 2002; 95:588-595.
4. Kiyosawa K, Uemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E: Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127:S17-S26.
5. Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, Liu HT, Hou SM, Wu CH, Chen TK: Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein. World J Gastroenterol 2003; 12:2666-2670.
6. Ohmoto K, Iguchi Y, Mimura N, Tsuduki M, Shimabara M, Kuboki M, Yamamoto S: Combined intraarterial 5-fluorouracil and intramuscular interferon-alpha therapy for advanced hepatocellular carcinoma. Hepatogastroenterology 2003; 50:1780-1782.
7. Leung TWT, Tang AMY, Zee B, Yu SCH, Lai PBS, Lau WY, Johnson PJ: Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94:421-427.
8. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94:435-442.
9. Yang TS, Chang HK, Chen JS, Lin YC, Liau CT, Chang WC: Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. J Gastroenterol 2004; 39:362-369.
10. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, Ito K: Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002; 80:143-148.
11. Yamasaki T, Kurokawa F, Takami T, Omori K, Kawaguchi K, Tsuchiya M, Yamamoto N, Okamoto M, Hironaka K, Kimura T, Terai S, Sakaida I, Okita K: Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study: Is a high dose of the biochemical modulator effective? Hepatol Res 2003; 27:36-44.
12. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Masuhara M, Okita K: Novel arterial infosion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 2002; 23:7-17.
13. Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL: Phase II study of the combination doxorubicin, interferon-alpha, and high dose tamoxifen treatment for advanced hepatocellular carcinoma. Hepatogastroenterology 2004; 51:815-819.
14. Kurokawa Y, Matoba R, Nagano H, Sakon M, Takemasa I, Nakamori S, Dono K, Umeshita K, Ueno N, Ishii S, Kato K, Monden M: Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. Clin Cancer Res 2004; 10:6029-6038.
15. Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Marubashi S, Miyamoto A, Nagano H, Dono K, Umeshita K, Nakamori S, Sakon M, Aozasa K, Monden M: Intestinal pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 39:793-797.